Vimarsana
Biggest News Aggregation in the World

Neurobehavioral Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neurobehavioral Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neurobehavioral Sciences Today - Breaking & Trending Today

University of Virginia Division of Perceptual Studies - Vimarsana News

University of Virginia Division of Perceptual Studies

University of Virginia Division of Perceptual StudiesNews, press releases, and expert sources for journalists in science, medicine & business

Vella Bioscience Launches Scientific Research Consortium for the Study of Women's Sexual Wellness - Vimarsana News

Vella Bioscience Launches Scientific Research Consortium for the Study of Women's Sexual Wellness

/PRNewswire/ -- Vella Bioscience, a biotech startup in service of female sexual empowerment, is today announcing the Consortium for the Study of Women's Sexual...

Nox Health Appoints Frances Thorndike, Ph.D. to lead Medical & Scientific Affairs - Vimarsana News

Nox Health Appoints Frances Thorndike, Ph.D. to lead Medical & Scientific Affairs

A pioneer who helped create Somryst, the first FDA-cleared prescription digital therapeutic for chronic insomnia, Dr. Thorndike brings deep expertise in insomnia, health economics and outcomes research to the Nox

FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD - Vimarsana News

FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults - Vimarsana News

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

/PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in...